Lara M Jeworowski
Overview
Explore the profile of Lara M Jeworowski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
146
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Muhlemann B, Trimpert J, Walper F, Schmidt M, Jansen J, Schroeder S, et al.
Proc Natl Acad Sci U S A
. 2024 Jul;
121(32):e2310917121.
PMID: 39078681
Severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) has developed substantial antigenic variability. As the majority of the population now has pre-existing immunity due to infection or vaccination, the use of...
2.
Jeworowski L, Muhlemann B, Walper F, Schmidt M, Jansen J, Krumbholz A, et al.
Euro Surveill
. 2024 Jan;
29(2).
PMID: 38214083
Variant BA.2.86 and its descendant, JN.1, of SARS-CoV-2 are rising in incidence across Europe and globally. We isolated recent JN.1, BA.2.86, EG.5, XBB.1.5 and earlier variants. We tested live virus...
3.
Schroder S, Richter A, Veith T, Emanuel J, Gudermann L, Friedmann K, et al.
Virol J
. 2023 Nov;
20(1):257.
PMID: 37940989
Background: Intrinsic fitness costs are likely to have guided the selection of lineage-determining mutations during emergence of variants of SARS-CoV-2. Whereas changes in receptor affinity and antibody neutralization have been...
4.
Wilks S, Muhlemann B, Shen X, Tureli S, LeGresley E, Netzl A, et al.
Science
. 2023 Oct;
382(6666):eadj0070.
PMID: 37797027
During the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, multiple variants escaping preexisting immunity emerged, causing reinfections of previously exposed individuals. Here, we used antigenic cartography to analyze patterns...
5.
Otto C, Schwarz T, Jeworowski L, Schmidt M, Walper F, Pache F, et al.
Mult Scler
. 2023 Mar;
29(7):884-888.
PMID: 36974938
Objective: To analyze anti-SARS-CoV-2-S1-IgG levels, avidity, Omicron BA.2 variant neutralizing capacity, and SARS-CoV-2-specific T cells in anti-CD20-treated patients with multiple sclerosis (aCD20pwMS) after two, three, or four COVID-19 vaccinations. Results:...
6.
Steiner S, Schwarz T, Corman V, Jeworowski L, Bauer S, Drosten C, et al.
J Clin Immunol
. 2023 Mar;
43(5):869-881.
PMID: 36932291
Purpose: Humoral and cellular immune responses were described after COVID-19 vaccination in patients with common variable immunodeficiency disorder (CVID). This study aimed to investigate SARS-CoV-2-specific antibody quality and memory function...
7.
Kreye J, Reincke S, Edelburg S, Jeworowski L, Kornau H, Trimpert J, et al.
iScience
. 2023 Mar;
26(4):106323.
PMID: 36925720
The recurrent emerging of novel viral variants of concern (VOCs) with evasion of preexisting antibody immunity upholds severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) case numbers and maintains a persistent...
8.
Niemeyer D, Stenzel S, Veith T, Schroeder S, Friedmann K, Weege F, et al.
PLoS Biol
. 2022 Nov;
20(11):e3001871.
PMID: 36383605
Epidemiological data demonstrate that Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) Alpha and Delta are more transmissible, infectious, and pathogenic than previous variants. Phenotypic properties of...
9.
Wilks S, Muhlemann B, Shen X, Tureli S, LeGresley E, Netzl A, et al.
bioRxiv
. 2022 Jul;
PMID: 35860221
During the SARS-CoV-2 pandemic, multiple variants escaping pre-existing immunity emerged, causing concerns about continued protection. Here, we use antigenic cartography to analyze patterns of cross-reactivity among a panel of 21...
10.
Veinalde R, Pidelaserra-Marti G, Moulin C, Jeworowski L, Kuther L, Buchholz C, et al.
Mol Ther Oncolytics
. 2022 Jan;
24:43-58.
PMID: 34977341
PD-1/PD-L1 checkpoint blockade has achieved unprecedented success in cancer immunotherapy. Nevertheless, many immune-excluded tumors are resistant to therapy. Combination with oncolytic virotherapy may overcome resistance by inducing acute inflammation, immune...